{{Infobox company
| name          = Ligand Pharmaceuticals
| logo          = 
| type          = [[Public company|Public]] 
| traded_as        = {{NASDAQ|LGND}}<br>[[S&P 600|S&P 600 Component]]
| foundation = September 1987
| location              = [[San Diego, California]], USA
| founder               = Brook Byers<ref>{{cite web|title=Ligand Pharmaceuticals Incorporated History|url=http://www.fundinguniverse.com/company-histories/ligand-pharmaceuticals-incorporated-history/|website=Funding Universe}}</ref>
| key_people            = John Higgins <small><br>([[Chief Executive Officer|CEO]])</small>
| industry              = Biopharmaceuticals
| products              = 
| revenue               = $48.1 million (2000)
| net_income            = 
| num_employees         = 20
| homepage              = [http://www.ligand.com Ligand.com]
| parent                = 
}}

'''Ligand Pharmaceuticals''' is a biopharmaceutical company based out of [[San Diego, California]] that develops programs through a portfolio of assorted strategies and properties in the pharmaceutical industry.

==History==
Ligand Pharmaceuticals, originally called Progenx, was founded in September 1987 by Brook Byers. The company's headquarters are in San Diego, California. In January 2007, John Higgins became the new CEO of Ligand and the business was stripped down from 66 employees to 18.<ref name=Forbes>{{cite web|title=Life After Loeb: Ligand Pharmaceuticals Prospers In Stripped-Down Mode|url=https://www.forbes.com/sites/danielfisher/2015/07/01/life-after-loeb-ligand-pharmaceuticals-prospers-in-stripped-down-mode/|website=Forbes|publisher=Forbes|accessdate=11 July 2015}}</ref> When John Higgins became CEO of Ligand Pharmaceuticals, [[Daniel S. Loeb|Daniel Loeb]] of [[Third Point Management]] bought into the biotech firm to cut its losses and grow revenue. Loeb invested $50 million, increased the company’s profit to $250 million, and brought back $68 million in stocks.<ref name=Forbes /><ref name="wall street">{{cite news|last1=Hernandez|first1=Angel|title=Ligand Pharmaceuticals Inc. (LGND) Profit Expected to Increase|url=http://www.wallstreet.org/ligand-pharmaceuticals-inc-lgnd-profit-expected-to-increase/|accessdate=10 February 2016|publisher=WallStreet|date=9 February 2016}}</ref>

As of June 2016, Ligand Pharmaceuticals' shares have returned 8.9%.<ref name="June 2016 returns">{{cite news|title=A WINNING STOCK THIS YEAR: LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND)|url=http://www.bibeypost.com/a-winning-stock-this-year-ligand-pharmaceuticals-incorporated-nasdaqlgnd/|accessdate=9 June 2016|publisher=Bibey Post|date=June 7, 2016}}</ref> In June 2016, Director John Kozarich sold 1,000 shares of Ligand Pharmaceuticals' stock at an average price of $117.42, for a total transaction of $117,420. He now owns 43,361 shares valued at $5,091,448.92.<ref name="Kozarich">{{cite news|last1=Robinson|first1=Mark|title=LIGAND PHARMACEUTICALS INC. (LGND) DIRECTOR JOHN W. KOZARICH SELLS 1,000 SHARES|url=http://www.lmkat.com/2016-06-04-ligand-pharmaceuticals-inc-lgnd-director-john-w-kozarich-sells-1000-shares/|accessdate=9 June 2016|publisher=LMKAT}}</ref>

==Partnerships==

Ligand Pharmaceuticals is partnered with approximately 120 pharmaceutical companies, which include Captisol and its partnerships.<ref name=Fool>{{cite web|title=3 Biotech Stocks That Could Grow Faster than Apple|url=http://www.fool.com/investing/general/2015/07/04/3-biotech-stocks-that-could-grow-faster-than-apple.aspx?source=eogyholnk0000001|publisher=The Motley Fool|accessdate=11 July 2015}}</ref>

===Captisol===

Ligand Pharmaceuticals' platform technology is Captisol, a chemically modified [[clathrate compound]] of the [[cyclodextrin]] class designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients.<ref name=Captisol>{{cite web|title=Captisol|url=http://www.captisol.com/|accessdate=11 July 2015}}</ref> The technology has enabled seven United States Food and Drug Administration approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs.<ref name="wall street"/>

==Collaborations==
{{div col}}
*[[Viking Therapeutics]]
*[[Novartis]]
*[[Onyx Pharmaceuticals]]
* [[Merck & Co.]]
*[[Bristol-Myers Squibb]]
*[[Pfizer]]
*[[Exelixis]]
*Chiva Pharmaceuticals
*[[Baxter International]]
*SAGE
*[[Lundbeck]]
*[[Retrophin]]
*Spectrum
*MEI Pharma
*[[Sanofi]]
*Melinta
*TG Therapeutics<ref name=Collaborations>{{cite web|title=Our Collaborations |url=http://www.ligand.com/our-collaborations |publisher=Ligand |accessdate=11 July 2015 |deadurl=yes |archiveurl=https://web.archive.org/web/20150716012425/http://www.ligand.com/our-collaborations |archivedate=16 July 2015 |df= }}</ref>
{{div col end}}

==Therapies==

Ligand Pharmaceutical's portfolios match the medical needs for patients with diabetes, hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, anemia, asthma, osteoporosis, thrombocytopenia, multiple myeloma, and fungal infections.<ref name=Yahoo>{{cite web|title=Ligand to Participate in Four Upcoming Investor Conferences|url=https://finance.yahoo.com/news/ligand-participate-four-upcoming-investor-210000617.html|accessdate=11 July 2015}}</ref>

==References==
{{reflist|2}}

[[Category:NASDAQ]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:1987 establishments in California]]
[[Category:Health care companies based in California]]
{{US-company-stub}}